From its initial use in the treatment of type 2 diabetes to its expansion to 12 indications such as obesity, cardiovascular disease, chronic kidney disease, and metabolic dysfunction related fatty liver disease (MASLD), the annual sales of GLP-1 drugs exceeded 100 billion dollars, and its research and development funding reached a historical peak of 21.72 million dollars in 2025
The key is to approach it with clear expectations, understand how it works, and make sure it aligns with your long-term goals
Chen J, Wang D, Wang F, Shi S, Chen Y, Yang B, Tang Y, Huang C
Compounded semaglutide contains the same active pharmaceutical ingredient as brand-name formulations and works through identical GLP-1 receptor mechanisms